Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
|
|
- Nigel Shields
- 5 years ago
- Views:
Transcription
1 Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA
2 There is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
3 Review the tenets of the Shared Decision Making Model Discuss the application of the Shared Decision Making model to diabetes care. Review the important clinical properties of the available medications for type 2 diabetes.
4 Physician Provider Proposes Treatment Patient expresses Resistance Provider presents Evidence Patient expresses Resistance Patient Both experience Frustration
5 Physician Patient Support patient Self Determination Develop relational autonomy. Educate, Provide Options Elicit preferences based on value judgements
6 Physician Patient
7 Insulin Biguanides (Metformin) Sulfonylureas (Glimepiride, Glipizide, Glyburide, etc.) Meglitinides (Repaglinide, etc.) Incretin Agonists (Exenatide, Liraglutide) Once Weekly (Exenatide, Dulaglutide, Albiglutide) DPP 4 Inhibitors (Sitagliptin, Saxagliptin, etc.) SGLT2 inhibitors (Canagliflozin, etc.) Thiazolidinediones (Pioglitazone) A Glucosidase Inhibitors (Acarbose, Miglitol) Bile Acid Sequestrant (Colesevalam) Amylin Mimetic (Pramlintide) Dopamine 2r Agonist (Bromocriptine)
8 Recommended first-line therapy by all major clinical practice guidelines: ADA, ACP, AACE Metformin offers multiple secondary benefits: Stabilization in body weight, or modest weight loss. Improvement in serum lipid profile (LDLc, TG) Likely reduction in cardiovascular events (UKPDS 10-year extension) Mortality / Survival benefit in certain populations Lower Cancer Incidence, fewer cancer deaths ADA Standards of Medical Care in Diabetes, 2014
9 Treatment is Individualized Cost? Efficacy? Side Effects? Effect on Weight? Hypoglycemia Risk? Secondary Benefits?
10 Efficacy: High. Can be titrated accurately. Hypoglycemia risk: Very high Weight: Typical gain 2 4 kg/year
11 High Doses Induces differentiation of new adipocytes from precursors. Cross agonist of IGF 1 receptor leading to somatotropic changes, pseudo acromegaloid features. High Doses Hypoglycemia increased intake of rescue carbohydrates. Hypoglycemia induces surge in cortisol, HGH, ghrelin. Often, high CHO intake to prevent hypoglycemia. Physiologic Doses Induces Lipoprotein Lipase expression and glucose uptake. Stimulates de novo biosynthesis of fatty acids and TG. Increased uptake of carbs and fats into tissues. Low Doses Suppresses glycosuria / polyuria. Low Doses Suppresses ketoacidosis. Blocks muscle catabolism. Allows anabolic effects of resistance training / exercise.
12 Worsening Glycemic Control Requiring more Insulin Insulin Therapy Worsening Insulin Resistance Weight Gain
13 Drug Name Avg Retail Cost* per month Metformin Index Insulin Glargine (Lantus ) $ / vial (33 units / d) 99 patients Insulin Detemir (Levemir ) $ / vial (33 units / d) 87 patients Insulin NPH (Humulin N) $66.88 / vial (33 units / d) 17 patients Ideal Patient: High Hemoglobin A1c (>10%). Longstanding burned out diabetes, or no response to sulfonylureas. Can tolerate weight gain. Regular / predictable diet and exercise regimen in order to minimize hypoglycemia risk. * Data are average of 1-month retail price from Walmart and Costco pharmacies. Generics used when possible Source: Virginia Mason Medical Center accessed on 12/3/2014.
14 Glimepiride (Amaryl ), Glipizide (Glucotrol ), Glyburide (Micronase ) Efficacy: Very good % A1c lowering Hypoglycemia risk: High Weight: Weight gain common Side Effects: Higher risk of progression to insulin requirement Secondary Benefits: convenient dosing
15 Drug Name Avg Retail Cost* per month Metformin Index Glipizide (Glucotrol ) $ patients Glyburide (Micronase ) $ patients Glimepiride (Amaryl ) $ patients Ideal Patient: Desire to minimize cost of medications. Desire to avoid injectables. Lean. Can tolerate some weight gain. Regular / predictable diet and exercise regimen in order to minimize hypoglycemia risk. * Data are average of 1-month retail price from Walmart and Costco pharmacies. Generics used when possible Source: Virginia Mason Medical Center accessed on 12/3/2014.
16 Exenatide (Byetta, Bydureon ), Liraglutide (Victoza ), Dulaglutide (Trulicity ), Albiglutide (Tanzeum ) Mechanism: Mimics the effects of anti diabetic hormone GLP 1 Blocks release of hormone glucagon Stimulates growth and secretory activity of pancreatic beta cells. Slows emptying of stomach reduced portion sizes. Stimulates NTS in brainstem weight loss.
17 Exenatide (Byetta, Bydureon ), Liraglutide (Victoza ), Dulaglutide (Trulicity ), Albiglutide (Tanzeum ) Efficacy: Intermediate % A1c lowering Side Effects: Nausea, vomiting (particularly after large meal) Diarrhea, headache Rare: hemorrhagic pancreatitis Potential: c cell hyperplasia (rodent model) Hypoglycemia risk: Minimal. Weight: Sustained modest weight loss.
18 Exenatide in lipid microsphere emulsion. Rapid release of surface bound exenatide. Slow release of embedded exenatide over 10 weeks (peaks at week 2 and weeks 6 7). Standard dosing: 2mg SQ, weekly. Supplied as single dose pens. Protocol for administration is complex, requires multiple steps. Bydureon prescribing information, Amylin Pharmaceuticals, 2012
19 Modified Human GLP 1 hormone, linked to albumin. Serum T1/2= 4 7 days. Supplied as single dose pens. Protocol for administration is complex, multiple steps, taking at least 15 minutes. Pancreatitis was observed in RCTs. Tanzeum prescribing information, 2014
20 Modified Human GLP 1 hormone, linked to Fc fragment of immunoglobulin. Serum T1/2= 5 days. Efficacy is inferior to liraglutide Supplied as single dose pens. Administration protocol is simpler. Significantly more expensive. Pancreatitis was observed in RCTs. Trulicity prescribing information, 2014
21 Drug Name Avg Retail Cost* per month Metformin Index Exenatide (Byetta ) $ patients Exenatide (Bydureon ) $ patients Liraglutide (Victoza ) $ patients Albiglutide (Tanzeum ) $ patients Dulaglutide (Trulicity ) $ patients Ideal Patient: Obese. Desire for modest weight loss. Desire to avoid hypoglycemia Suitable insurance. Willing to pay more for medications. * Data are average of 1-month retail price from Walmart and Costco pharmacies. Generics used when possible Source: Virginia Mason Medical Center accessed on 12/3/2014.
22 Sitagliptin (Januvia ), Saxagliptin (Onglyza ), Linagliptin (Tradjenta ), Alogliptin (Nesina ) Mechanism: Blocks the degradation of the anti diabetic hormone GLP 1 Blocks release of hormone glucagon Stimulates growth and secretory activity of pancreatic beta cells.
23 Sitagliptin (Januvia ), Saxagliptin (Onglyza ), Linagliptin (Tradjenta ), Alogliptin (Nesina ) Efficacy: % lowering of HgbA1c Side Effects: generally well tolerated. Nausea is generally mild Hypoglycemia risk: minimal. Weight: Neutral. No significant gain or loss. Secondary Benefits: Once Daily Dosing
24 Drug Name Avg Retail Cost* per month Metformin Index Sitagliptin (Januvia ) $ patients Linagliptin (Tradjenta ) $ patients Alogliptin (Nesina ) $ patients Saxagliptin (Onglyza ) $ patients Ideal Patient: Desires convenience of once daily pill dosing. Desires a very mild side effect profile. Desires to avoid weight gain. Desires oral medications over injectables. Willing to pay more for medications. * Data are average of 1-month retail price from Walmart and Costco pharmacies. Generics used when possible Source: Virginia Mason Medical Center accessed on 12/3/2014.
25 Efficacy: Modest % lowering of HgbA1c Side Effects: Fluid Retention Contraindicated in heart failure. Avoid in heart disease Weight: Typical gain 2 4 kg/year. Hypoglycemia risk: minimal. Secondary Benefit: Once Daily Dosing, treats Non Alcoholic Fatty Liver Disease
26 Drug Name Avg Retail Cost* per month Metformin Index Pioglitazone (Actos ) $ patients Ideal Patient: No heart disease. Desire to minimize cost of medications. Desire convenience of once daily pill dosing. Desire oral medications over injectables. Willing to tolerate weight gain. * Data are average of 1-month retail price from Walmart and Costco pharmacies. Generics used when possible Source: Virginia Mason Medical Center accessed on 12/3/2014.
27 Acarbose (Precose ), Miglitol (Glycet ) Mechanism: Blocks intestinal alpha glucosidase impairs digestion of disaccharides / polysaccharides Reduces postprandial glucose. Unabsorbed carbohydrates are fermented into gas by intestinal flora.
28 Efficacy: Decent % lowering of HgbA1c Side Effects: Flatulence (esp after high carb meal), can cause uncomfortable abdominal cramps / colicky pain. Weight: Neutral. Hypoglycemia risk: Minimal. Secondary Benefits: Fewer Heart attacks observed in clinical trials. Also indicated for prevention of diabetes.
29 Drug Name Avg Retail Cost* per month Metformin Index Acarbose (Precose ) $ patients Ideal Patient: Desire oral medications over injectables. Desire modest weight loss. Desire to reduce medication costs. Willing / able to significantly reduce carb intake, or tolerate significant gas & flatulence. * Data are average of 1-month retail price from Walmart and Costco pharmacies. Generics used when possible Source: Virginia Mason Medical Center accessed on 12/3/2014.
30 Canagliflozin (Invokana ): approved by FDA in 2013 Dapagliflozin (Farxiga ): approved by FDA in 2014 Empagliflozin (Jardiance ): approved by FDA in 2014 Works by blocking the SGLT2 glucose symporter in the proximal tubule of the nephron. Effect: far greater excretion of glucose in urine. Glucose pulls salt/water into urine by osmosis osmotic diuresis dehydration / thirst.
31 Adverse effects: Dehydration can potentially injure kidneys Risk of UTIs & genitourinary infections Especially, Females Dapagliflozin: Increased Bladder Cancer in RCTs New Medication class: unknown potential risks.
32 Efficacy: Decent. A1c reduction % Side Effects: Polyuria, hypovolemia (even kidney Injury). Glycosuria UTIs & genitourinary infections. Dapagliflozin: increased bladder Ca in RCTs. Hypoglycemia risk: Intermediate. Slightly higher risk vs. placebo. Weight: Modest weight reduction 2 4% Canagliflozin (Invokana) 2012 Virginia Prescribing Mason Medical Information Center
33 Drug Name Avg Retail Cost* per month Metformin Index Canagliflozin (Invokana ) $ patients Dapagliflozin (Farxiga ) $ patients Empagliflozin (Jardiance ) $ patients Ideal Patient: Desires convenience of once daily pill dosing. Desires modest weight loss. Desires oral medications over injectables. Willing to pay more for medications. * Data are average of 1-month retail price from Walmart and Costco pharmacies. Generics used when possible Source: Virginia Mason Medical Center accessed on 12/3/2014.
34 Support patient Self Determination Develop relational autonomy. Educate, Provide Options Elicit preferences based on value judgements
35
36
37
38 FDA approved in 2009 Treatment of Type 2 DM In addition to Metformin, Sulfonylurea, or Insulin Unknown Mechanism of Action Efficacy: Modest Hgb A1c benefit: 0.5% Adverse Effects: Nausea, dizziness, rhinitis common. Pijl H, et al Diabetes Virginia Mason Care Medical 23: Center
39 FDA approved in 2008 for Treatment of Diabetes: In addition to Metformin, SU, or Insulin Unknown Mechanism of Action GLOWS Trial Improved LDLc Modest Hgb A1c reduction (0.5%, greater in patients with higher starting A1c). ADVERSE EFFECTS: 9/29 (29.0%) subjects in colesevelam arm 3/34 (8.8%) subjects in placebo arm Gastrointestinal disorders 22.6% Constipation 19.4% Zieve FJ, et 2012 al. Virginia Clinical Mason Medical Therapeutics: Center 29(1): 74-83
Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationNon-Insulin Diabetes Medications Summary
Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationDIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0
Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationDiabetes 2016: Strategies for achieving optimal diabetes control
PHASE Safety Net Community Benefit Diabetes 2016: Strategies for achieving optimal diabetes control Presented by: Lisa Gilliam, MD, PhD Clinical Leader Diabetes Program Kaiser Permanente Northern California
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationPhysician Drug Reference Chart for Diabetes Antidiabetic Medications
Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationDiabetes Treatment Guidelines
Diabetes Treatment Guidelines For more comprehensive information about current approaches to the diagnosis and treatment of diabetes, visit the American Diabetes Association Standards of Medical Care 2018
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationType 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18
Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 No conflicts of interest Objectives for this talk Update on non-insulin drug therapy fro type 2 DM Appropriate use of insulin in type 2 DM ADA
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More information1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime
Disclosures Current Diabetes Medications None Claire Baker, M.D. Diabetes & Endocrine Associates January 24, 2018 Objectives Identify categories of diabetes medications Understand the pharmacology of diabetes
More informationImproving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes
Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Duality Statement Dr. Reid is a Speaker and Consultant
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationWelcome to the PHASE Learning Community! October 31, 2018
Welcome to the PHASE Learning Community! October 31, 2018 Webinar Housekeeping 1. Dial in for audio: 303-248-0285, Access Code: 5617817 2. Lines are muted. You can chat in questions or unmute your line
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationCollaborative Practice Agreement
Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More informationPharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN
Pharmacology Kacy Aderhold, MSN, APRN-CNS, CMSRN Biguanides Decreases hepatic glucose production and improves insulin sensitivity (increases number of insulin receptors) Common Adverse Reaction: diarrhea
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationDIABETES UPDATE 2018
DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationType 2 Diabetes Mellitus hypoglycaemic agents
Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationHealthy You: A Guide to Diabetes Self-Care SURVIVAL SKILLS
Healthy You: A Guide to Diabetes Self-Care SURVIVAL SKILLS Table of Contents Introduction 3 Monitoring Your Diabetes 7 Medications 11 Problem Solving 24 Healthy Eating with Diabetes 26 Managing Sick Days
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationGlycemic Management of Type 2 Diabetes. Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University
Glycemic Management of Type 2 Diabetes Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University 1 None Disclosures Learning Objectives Understand the
More informationWhat You Should Know About Diabetes. Laura Bingell RN Transition Center Nurse for MFP (607)
What You Should Know About Diabetes Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org Diabetes Mellitus (DM) a group of diseases marked by high blood glucose levels. 9.3%
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More information2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists
WAYNE STATE UNIVERSITY COLLEGE OF PHARMACY & HEALTH SCIENCES FEBRUARY 28, 2016 The Evolving Armamentarium for Type 2 Diabetes: Clinical Assistant Professor, Department of Pharmacy Practice Ambulatory Care
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationDiabetes management in liver and kidney disease
Diabetes management in liver and kidney disease Epidemiology 1 Clinical case A 59 year old man with alcoholic cirrhosis; portal hypertension; mild encephalopathy Fasting plasma glucose - 103, March 2016;
More informationcontinuing education for pharmacists
continuing education for pharmacists 2016 AACE/ACE Guidelines on Type 2 Diabetes Management and New Glycemic Control Agents Amanda R. Kriesen, R.Ph., PharmD, and Erin Bastick, R.Ph., PharmD Volume XXXV,
More informationDate of Review: September 2016 Date of Last Review: September 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationClinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018
Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018 RACHEL NAIDA, PHARMD, CDE CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF NEW ENGLAND COLLEGE OF PHARMACY
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationNew Medications and Prescribing Methods for Diabetic Patients
New Medications and Prescribing Methods for Diabetic Patients Jeffrey Stroup, PharmD, BCPS, FCCP Professor of Medicine Oklahoma State University Center for Health Sciences Department of Internal Medicine
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationRemote attendees, please mute your phones as a courtesy thank you!
Welcome! Remote attendees, please mute your phones as a courtesy thank you! Diabetes: The Ins and Outs of Insulin CareOregon Pharmacy Today s Agenda Introduction 8:00-8:15am RN perspective 8:15 8:45am
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationDeaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals
Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More information2018 Diabetes Summit Managing Diabetes: An Art and a Science
2018 Diabetes Summit Managing Diabetes: An Art and a Science Natasha Petry, PharmD, BCACP NDSU College of Health Professions, School of Pharmacy, Department of Pharmacy Practice Patient-Centered Medical
More informationRational Goal-Setting and Management of Diabetes in the Elderly
Rational Goal-Setting and Management of Diabetes in the Elderly Michael Shannon, MD Medical Director, Physicians of Southwest Washington Clinical Assistant Professor, University of Washington Outline of
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationDiabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:
Section #1 OBJECTIVE Diabetes Update Fall 2017 Lyle Myers BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2 DIABETES Clinical features: - age at onset - body weight/bmi - family history - treatment history -
More informationIndividualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD
Individualizing Type 2 Diabetes Management Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Harsh Statistics 30.3 million (9.4% of population) in US had DM in 2015 The percent of population with DM increases
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More information